Skip to main content
Clinical Trials/NCT02191020
NCT02191020
Completed
Not Applicable

Multi-center, Randomized, Double Blind, Placebo Parallel-Controlled Study of the Efficacy and Safety of Total Glucosides of Paeony Combined With Acitretin Capsules to Treat Psoriasis Vulgaris

Xijing Hospital1 site in 1 country108 target enrollmentFebruary 2013

Overview

Phase
Not Applicable
Intervention
Total glucosides of paeony & Acitretin Capsules
Conditions
Psoriasis
Sponsor
Xijing Hospital
Enrollment
108
Locations
1
Primary Endpoint
Reduction in Psoriasis Area and Severity Index
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This is a randomized, double blind, placebo parallel-controlled, multi-center clinical trial. Patients with psoriasis vulgaris were randomly divided into the experiment group (treated with TGP combined with acitretin capsules) and control group (treated with placebo combined with acitretin capsules).The treatment lasted 12 weeks. The efficacy and safety were evaluated at the baseline, as well as 2, 4, 8 and 12 weeks after the beginning of treatment.The investigator's hypothesis TGP combined with Acitretin Capsulesin is more safe and effective than Acitretin Capsulesin to treat Psoriasis Vulgaris.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
October 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xijing Hospital
Responsible Party
Principal Investigator
Principal Investigator

xjpfW

Chief in Department of Dermatology

Xijing Hospital

Eligibility Criteria

Inclusion Criteria

  • Meet the following conditions
  • Diagnosed according to Classification criteria for Psoriasis vulgaris;
  • Patients aged 18 to 65 years (to the date of screening);
  • PASI grade\>7point\<20 point;
  • Not treatment in the Topical corticosteroids、Immunosuppresso、Biologicals agents or Tretinoin cream、Phototherapy nearly one months before enrolled.
  • Understanding the whole process of the study, voluntary participation and signed the informed consent;
  • Patient compliance is good, can guarantee in course of observation.

Exclusion Criteria

  • One of the following is not included in this study:
  • Pregnant women, ready to pregnant or lactating women;
  • Known to root of herbaceous peony total glycosides (TGP) drug allergy;
  • Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history
  • Patients is liver function abnormal persons (ALT above the center laboratory normal limit) or hepatitis b patient grain carriers;
  • Need insulin control of diabetes; High blood pressure did not get good controller ;
  • Patients with white blood cells \<4.0 × 109 / L, or a definite anemia (hemoglobin less than 100g / L), or platelets \<100 × 109 / L, or other blood disease;
  • Patients with chronic diarrhea, or peptic ulcer nearly 1 year;
  • Patients suffering from malignant tumor;
  • Patients suffering from acute and chronic infectious diseases;

Arms & Interventions

Total glucosides of paeony & Acitretin Capsules

During the first week,0.6g,oral,b.i.d.During the other weeks,0.6g,oral,t.i.d

Intervention: Total glucosides of paeony & Acitretin Capsules

Acitretin Capsules

20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.

Intervention: Acitretin Capsules

Outcomes

Primary Outcomes

Reduction in Psoriasis Area and Severity Index

Time Frame: week 0 and week 12

After 12 weeks treatment, relative to baseline, the proportion of patients achieving a 50% reduction in Psoriasis Area and Severity Index 50 (PASI50) was 90% in the experiment group and 70.5% in the control group (P\<0.05).

Secondary Outcomes

  • incidence of elevated Alanine aminotransferase(week 0 and week12)

Study Sites (1)

Loading locations...

Similar Trials